DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Otros (Other)
Transcription factor NRF2: New therapeutic approach to modify Parkinson's disease progression
The lack of neuroprotective therapies for Parkinson's disease (PD) is a critical issue with significant societal and scientific relevance. The medications available, such as levodopa and dopamine agonists, focus solely on managing symptoms by temporarily replenishing dopamine or mimicking its effects. While these treatments provide relief, they do not address the root cause of the disease, allowing neurodegeneration to continue unchecked. This is why it is necessary to find new therapeutic targets that slow down the progression of the neurodegenerative process. The search for a single target capable of modulating oxidative stress, neuroinflammation, and the alteration of proteostasis associated with PD has focused on the transcription factor NRF2. Genetic variations in the NRF2 encoding NFE2L2 gene promoter that may influence disease risk and onset age have been associated with disease risk or prevention. This basic leucine-zipper protein orchestrates the expression of a battery of cytoprotective genes, all of which share a specific enhancer known as the antioxidant response element (ARE). These genes are pivotal in a variety of cellular processes, including detoxification reactions across phases I, II, and III, metabolism of glutathione and the peroxiredoxin/thioredoxin system, NADPH generation, neuroinflammation, iron management/ferroptosis, and proteostasis. Given NRF2's ability to modulate several PD's key features, various pharmacological approaches have been explored. This chapter examines the role of NRF2 in PD pathogenesis and discusses promising compounds validated in mouse models that warrant clinical trial, This work was supported by MINECO (Grants PID2022-137065OB-I00 to I.L.-B.; PID-2021-122766OB-100, PDC2021-121421-I00, PDC2022-133765-I00 to AIR and AC; PID2022-137011OA-I00/AEI/10.13039/501100011033/FEDER, EU to NE), ISCiii CIBERNED (CB06/05/0089 to IL-B and NE; CB06/05/0010 to AC and AIR) and the Autonomous Community of Madrid (P2022/BMD-7230) to AIR and AC.
NE is funded by a Ramón y Cajal Fellowship (RYC2021-034267-I) from the Spanish Ministry of Science and Innovation MCIN/AEI/10.13039/501100011033., Peer reviewed
Proyecto:
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2022-137065OB-I00
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2021-122766OB-I00
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 PDC2021-121421-I00
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PDC2022-133765-I00
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2022-137011OA-I00